Published in Leukemia on February 01, 1996
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
The United Kingdom Childhood Cancer Study: objectives, materials and methods. UK Childhood Cancer Study Investigators. Br J Cancer (2000) 2.37
Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A (2001) 1.93
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2010) 1.37
MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica (2011) 1.21
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res (2011) 1.16
FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer (2010) 0.99
Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells Mol Dis (2010) 0.95
Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.93
Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep (2012) 0.89
High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome. Leukemia (2013) 0.88
High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols. Haematologica (2013) 0.85
Somatic Mutation Allelic Ratio Test Using ddPCR (SMART-ddPCR): An Accurate Method for Assessment of Preferential Allelic Imbalance in Tumor DNA. PLoS One (2015) 0.79
Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease. Mol Cytogenet (2013) 0.77
Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia. Clin Med Insights Oncol (2017) 0.75
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 4.59
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol (1997) 3.05
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood (1995) 2.89
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys (1995) 2.01
Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med (1993) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med (1997) 1.88
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol (2000) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 1.83
Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood (1991) 1.74
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst (1996) 1.54
Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol (1998) 1.52
Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med (1987) 1.52
Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant (2001) 1.52
Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther (1994) 1.51
Lineage switch in acute leukemia. Blood (1984) 1.51
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood (2001) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood (1993) 1.47
Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood (1992) 1.42
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol (1991) 1.42
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst (2012) 1.41
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40
Characterization of cyclophosphamide-rat model of cryptosporidiosis. Infect Immun (1987) 1.38
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer (2001) 1.36
Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood (1996) 1.32
Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res (1997) 1.31
Late mortality of long-term survivors of childhood cancer. J Clin Oncol (1997) 1.31
Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med (1993) 1.31
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood (1994) 1.29
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest (1994) 1.29
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol (2001) 1.29
Characterization of a dexamethasone-treated rat model of cryptosporidial infection. J Infect Dis (1988) 1.28
Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol (2000) 1.28
Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia (2001) 1.27